Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort

被引:56
作者
Hountondji, Lina [1 ]
De Matos, Christophe Ferreira [2 ]
Lebosse, Fanny [3 ]
Quantin, Xavier [4 ]
Lesage, Candice [5 ]
Palassin, Pascale [6 ]
Rivet, Valerian [2 ]
Faure, Stephanie [1 ]
Pageaux, Georges-Philippe [1 ]
Assenat, Eric [7 ]
Alric, Laurent [8 ]
Zahhaf, Amel [9 ]
Larrey, Dominique [9 ]
Viel, Philine Witkowski Durand [10 ]
Riviere, Benjamin [11 ]
Janick, Selves [12 ]
Dalle, Stephane [13 ]
Maria, Alexandre Thibault Jacques [14 ]
Comont, Thibaut [2 ]
Meunier, Lucy [9 ,15 ]
机构
[1] Montpellier Univ Hosp, St Eloi Hosp, Dept Liver Transplantat, Montpellier, France
[2] Toulouse Univ Hosp, Dept Internal Med, IUCT Oncopole, Toulouse, France
[3] Hosp Civils Lyon, Croix Rousse Hosp, Lyon Liver Inst, Dept Hepatol, Lyon, France
[4] Montpellier Univ Hosp, Montpellier Canc Inst, Dept Med Oncol, Montpellier, France
[5] Montpellier Univ Hosp, St Eloi Hosp, Dept Dermatol, Montpellier, France
[6] Montpellier Univ Hosp, Lapeyronie Hosp, Dept Med Pharmacol & Toxicol, Montpellier, France
[7] Montpellier Univ Hosp, St Eloi Hosp, Dept Oncol, Montpellier, France
[8] Toulouse Univ Hosp, Purpan Hosp, Dept Internal Med & Digest Dis, Toulouse, France
[9] Montpellier Univ Hosp, St Eloi Hosp, Dept Liver Transplantat, REFHEPS, Montpellier, France
[10] Beziers Hosp, Internal Med, Beziers, France
[11] Univ Montpellier, Montpellier Univ Hosp, Dept Pathol, Montpellier, France
[12] Oncopole, Dept Pathol, Toulouse, France
[13] Hosp Civils Lyon, Lyon Sud Hosp, Lyon Canc Inst, Dept Dermatol, Lyon, France
[14] Montpellier Univ Hosp, St Eloi Hosp, Inst Regenerat Med & Biotherapy IRMB, Internal Med & Immunooncol MedI2O, Montpellier, France
[15] Montpellier Univ Hosp, St Eloi Hosp, Dept Liver Transplantat, REFHEPS, 80 Ave Augustin Fl, F-34090 Montpellier, France
关键词
Immune checkpoint inhibitors; Immune-related adverse events; Drug-induced liver injury; Cancer; Hepatitis; Cholangitis; CAUSALITY ASSESSMENT; ADVERSE REACTIONS; CHOLANGITIS; NIVOLUMAB; THERAPY; DRUGS;
D O I
10.1016/j.jhepr.2023.100719
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background & Aims: Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our study was to describe the different clinical patterns of ICI-induced hepatitis and to assess their outcome.Methods: We conducted a retrospective observational study of patients with checkpoint inhibitor-induced liver injury (CHILI) discussed in multidisciplinary meetings between December 2018 and March 2022 in three French centres specialised in ICI toxicity management (Montpellier, Toulouse, Lyon). The hepatitis clinical pattern was analysed by the ratio of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (R value = (ALT/ULN)/(ALP/ULN)) for characterisation as cholestatic (R <-2), hepatocellular (R >-5), or mixed (2 5).Results: We included 117 patients with CHILI. The clinical pattern was hepatocellular in 38.5%, cholestatic in 36.8%, and mixed in 24.8% of patients. High-grade hepatitis severity (grade >-3 according to the Common Terminology Criteria for Adverse Events system) was significantly associated with the hepatocellular hepatitis (p <0.05). No cases of severe acute hepatitis were reported. Liver biopsy was performed in 41.9% of patients: granulomatous lesions, endothelitis, or lymphocytic cholangitis were described. Biliary stenosis occurred in eight patients (6.8%) and was significantly more frequent in the cholestatic clinical pattern (p < 0.001). Steroids alone were mainly administered to patients with a hepatocellular clinical pattern (26.5%), and ursodeoxycholic acid was more frequently used in the cholestatic pattern (19.7%) than in the hepatocellular or mixed clinical pattern (p <0.001). Seventeen patients improved without any treatment. Among the 51 patients (43.6%) rechallenged with ICIs, 12 (23.5%) developed CHILI recurrence.Conclusions: This large cohort indicates the different clinical patterns of ICI-induced liver injury and highlights that the cholestatic and hepatocellular patterns are the most frequent with different outcomes.Impact and Implications: ICIs can induce hepatitis. In this retrospective series, we report 117 cases of ICI-induced hepatitis, mostly grades 3 and 4. We find a similar distribution of the different patterns of hepatitis. ICI could be resumed without systematic recurrence of hepatitis.& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:13
相关论文
共 40 条
[1]
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report [J].
Agrawal, Rohit ;
Guzman, Grace ;
Karimi, Saman ;
Giulianotti, Pier Cristoforo ;
Lora, Alfredo Jose Mena ;
Jain, Shikha ;
Khan, Meshaal ;
Boulay, Brian R. ;
Chen, Yolande .
WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (20) :7124-7129
[2]
EASL Clinical Practice Guidelines: Drug-induced liver injury [J].
Andrade, Raul J. ;
Aithal, Guruprasad P. ;
Bjornsson, Einar S. ;
Kaplowitz, Neil ;
Kullak-Ublick, Gerd A. ;
Karlsen, Tom H. .
JOURNAL OF HEPATOLOGY, 2019, 70 (06) :1222-1261
[3]
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].
Andre, T. ;
Shiu, K-K ;
Kim, T. W. ;
Jensen, B., V ;
Jensen, L. H. ;
Punt, C. ;
Smith, D. ;
Garcia-Carbonero, R. ;
Benavides, M. ;
Gibbs, P. ;
de la Fouchardiere, C. ;
Rivera, F. ;
Elez, E. ;
Bendell, J. ;
Le, D. T. ;
Yoshino, T. ;
Van Cutsem, E. ;
Yang, P. ;
Farooqui, M. Z. H. ;
Marinello, P. ;
Diaz, L. A., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218
[4]
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].
Arbour, Kathryn C. ;
Mezquita, Laura ;
Long, Niamh ;
Rizvi, Hira ;
Auclin, Edouard ;
Ni, Andy ;
Martinez-Bernal, Gala ;
Ferrara, Roberto ;
Lai, W. Victoria ;
Hendriks, Lizza E. L. ;
Sabari, Joshua K. ;
Caramella, Caroline ;
Plodkowski, Andrew J. ;
Halpenny, Darragh ;
Chaft, Jamie E. ;
Planchard, David ;
Riely, Gregory J. ;
Besse, Benjamin ;
Hellmann, Matthew D. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+
[5]
CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .2. AN ORIGINAL MODEL FOR VALIDATION OF DRUG CAUSALITY ASSESSMENT METHODS - CASE-REPORTS WITH POSITIVE RECHALLENGE [J].
BENICHOU, C ;
DANAN, G ;
FLAHAULT, A .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1331-1336
[6]
Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort [J].
Berry, Philip ;
Kotha, Sreelakshmi ;
Zen, Yoh ;
Papa, Sophie ;
El Menabawey, Tareq ;
Webster, George ;
Joshi, Deepak ;
Heneghan, Michael .
LIVER INTERNATIONAL, 2023, 43 (01) :147-154
[7]
EASL Clinical Practice Guidelines: Management of cholestatic liver diseases [J].
Beuers, Ulrich ;
Boberg, Kirsten M. ;
Chapman, Roger W. ;
Chazouilleres, Olivier ;
Invernizzi, Pietro ;
Jones, David E. J. ;
Lammert, Frank ;
Pares, Albert ;
Trauner, Michael .
JOURNAL OF HEPATOLOGY, 2009, 51 (02) :237-267
[8]
Liver biopsy findings in patients on immune checkpoint inhibitors [J].
Cohen, Justine V. ;
Dougan, Michael ;
Zubiri, Leyre ;
Reynolds, Kerry L. ;
Sullivan, Ryan J. ;
Misdraji, Joseph .
MODERN PATHOLOGY, 2021, 34 (02) :426-437
[9]
CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .1. A NOVEL METHOD BASED ON THE CONCLUSIONS OF INTERNATIONAL CONSENSUS MEETINGS - APPLICATION TO DRUG-INDUCED LIVER INJURIES [J].
DANAN, G ;
BENICHOU, C .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1323-1330
[10]
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors [J].
De Martin, Eleonora ;
Michot, Jean-Marie ;
Rosmorduc, Olivier ;
Guettier, Catherine ;
Samuel, Didier .
JHEP REPORTS, 2020, 2 (06)